Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioCardia ( (BCDA) ) just unveiled an update.
On February 3, 2026, BioCardia announced that echocardiography data from its CardiAMP Cell Therapy for the treatment of heart failure were accepted for a Late Breaking Clinical Trial Oral Presentation at the Technology and Heart Failure Therapeutics Meeting, scheduled for March 2–4, 2026, in Boston, Massachusetts. The data, to be presented on March 2 by CardiAMP HF Trial National Co-Principal Investigator Dr. Amish Raval, highlight investigational autologous cell therapy aimed at curbing pathological ventricular remodeling in chronic ischemic heart failure patients with reduced ejection fraction, underscoring BioCardia’s advancing clinical profile and the growing recognition of its FDA Breakthrough-designated, catheter-based therapy, which is supported by the Maryland Stem Cell Research Fund and reimbursed by the Centers for Medicare and Medicaid Services.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
Spark’s Take on BCDA Stock
According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.
The score is primarily constrained by weak financial performance (no meaningful revenue, sustained losses, and significant cash burn). Partially offsetting this are moderately supportive near-term technicals and a more positive earnings-call backdrop driven by clinical/regulatory progress and stated cash runway into 2026, while valuation remains hard to justify due to negative earnings and no dividend.
To see Spark’s full report on BCDA stock, click here.
More about BioCardia
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics focused on treating cardiovascular and pulmonary diseases. Its pipeline includes the CardiAMP autologous and CardiALLO allogeneic cell therapy platforms, with three cardiac clinical-stage product candidates enabled by proprietary Helix biotherapeutic delivery, Morph vascular navigation systems, and the forthcoming Heart3D fusion imaging platform, alongside selective partnerships to support delivery of peer-developed biologic therapies.
Average Trading Volume: 76,458
Technical Sentiment Signal: Sell
Current Market Cap: $13.05M
See more data about BCDA stock on TipRanks’ Stock Analysis page.